Affimed N.V.
AFMDDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AFM13 | Phase 2 | Peripheral T Cell Lymphoma | - | - |
Frequently asked questions
What is in Affimed N.V.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Affimed N.V.'s (AFMD) pipeline across Phase 2. Its lead program is AFM13 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Affimed N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Affimed N.V. (AFMD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AFMD biotech catalysts?→
Add AFMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Affimed N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.